##  [AUTHORIZATION PROCESS FOR NDA & IND APPLICATIONS: A US & EU Comparative Analysis](/index%2ephp/white-papers/authorization-process-for-nda-ind-applications-a-us-eu-comparative-analysis) 

- [Medicinal Products](/index%2ephp/white-papers-categories/medicinal-products)
- [Publishing and Submission](/index%2ephp/white-papers-categories/publishing-and-submission)





 ![AUTHORIZATION PROCESS FOR NDA & IND APPLICATIONS: A US & EU Comparative Analysis]()

An overview of the drug approval process of the Investigational New Drug (IND) and New Drug Application (NDA) submissions has been explored. The whitepaper discusses the differences between the two regulatory submissions and their review processes. It also compares the timelines for IND and NDA submissions in the United States (US) and the European Union (EU). The paper explores different approaches that drug sponsors can adopt to expedite the approval process and reduce the time to market the drug while maintaining compliance with regulatory requirements.



Fill the form below to download the White Paper

 You must have JavaScript enabled to use this form.

  

  

  

 How did you hear about us?Search EngineE-mail CampaignGoogle AdsSocial MediaLink from another websiteColleague’s RecommendationNewsletterPrinted BrochureOther 

  

 

 

     I have read the [privacy policy](https://www.freyrsolutions.com/privacy-policy) 



 

 Submitted Page URL  

 Website URL  

 Content Type  

 Form Name